Compass Pathways Nears NDA Completion, but Launch Risks Linger

What happened

Compass Pathways announced during its Q3 earnings call that it expects to complete the rolling New Drug Application (NDA) for COMP360 within two weeks, with the submission including data from two statistically significant Phase 3 trials in treatment-resistant depression. This timing is consistent with prior guidance to finish the NDA in Q4 2026 and supports a potential U.S. launch in the first half of 2027. However, the announcement does not address critical post-approval hurdles such as DEA rescheduling, REMS implementation, and treatment-site certification, which remain unresolved. The company's cash position of $433.3 million as of June 30, 2026 provides runway into 2028, but the stock at approximately $12.3 already prices in much of the regulatory upside. While NDA completion is a necessary step, it is not sufficient to de-risk the commercial pathway.

Implication

Investors should monitor subsequent disclosures on DEA rescheduling, REMS details, and certified site count. Failure to provide concrete launch-readiness milestones by early 2027 would undermine the H1 2027 launch assumption and support reducing exposure. Conversely, tangible progress in these areas would strengthen the case for an eventual upward re-rating.

Thesis delta

The thesis remains WAIT. The confirmation that NDA completion is expected within two weeks aligns with the base case of a Q4 2026 filing and slightly increases confidence in meeting that milestone. However, it does not address the post-approval launch risks that are central to the investment case, so the fundamental view is unchanged.